BridgeMD
New treatment option for Polycystic Ovary Syndrome (PCOS) Women
Official title Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
ClinicalTrials.gov ID: NCT06896981
What this study is testing
What is Metformin with Semaglutide?
Metformin with Semaglutide is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for polycystic ovary syndrome (pcos) women.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that is frequently associated with metabolic features, including obesity. Improvement of metabolic manifestations helps in the control of symptoms, including subfertility.
- Phase 3: a large, late-stage study
- Time commitment: about 12 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 10 to 45, women only
You may be able to join if
- Reproductive-aged women with PCOS diagnosed according to International evidence based guidelines 2023 and obesity
You likely can't join if
- Having DM, other significant systemic diseases- chronic kidney disease (eGFR \ 3 × ULN), and heart failure
- Patients having PCOS mimicking endocrine disorders (untreated thyroid dysfunctions, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's...
- Those taking any other weight loss medications (eg., orlistat, liraglutide) within the last 3 months
- Those who have undergone bariatric surgery
- Any conditions causing weight loss (thyrotoxicosis, Addison's disease, chronic infection, connective tissue disorder, cancer, etc)
- Secondary causes of obesity (major mood disorders, steroids, valproate, oral contraceptives, etc)
See the full eligibility criteria
- Reproductive-aged women with PCOS diagnosed according to International evidence based guidelines 2023 and obesity
- Having DM, other significant systemic diseases- chronic kidney disease (eGFR \ 3 × ULN), and heart failure
- Patients having PCOS mimicking endocrine disorders (untreated thyroid dysfunctions, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, acromegaly, hypothalamic disorder etc.)
- Those taking any other weight loss medications (eg., orlistat, liraglutide) within the last 3 months
- Those who have undergone bariatric surgery
- Any conditions causing weight loss (thyrotoxicosis, Addison's disease, chronic infection, connective tissue disorder, cancer, etc)
- Secondary causes of obesity (major mood disorders, steroids, valproate, oral contraceptives, etc)
- Contraindications for semaglutide: personal or family history of medullary carcinoma of the thyroid, history of acute pancreatitis, gallbladder disease
- Planning for pregnancy or current pregnancy/ lactation
The study team makes the final eligibility decision.
Where it's taking place
- Dhaka, Dhaka Division, Bangladesh
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling female, 10 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dhaka, Dhaka Division, Bangladesh. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.